{"filings":[{"id":93791,"accession_number":"0001576280-26-000024","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q1 revenue rises 48% to $301.7 million, boosts 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue increased 48% to $301.7M driven by Oncology revenue growth of 36% and Screening revenue surge to $41.6M.","Net loss per share widened to $0.85 from $0.77; non-GAAP net loss per share improved to $0.45 from $0.49.","Raised 2026 revenue guidance to $1.30-$1.32B (32-34% growth), up from prior $1.25-$1.28B; Oncology volume growth expected >35%.","Shield screening tests reached 44,000 in Q1; 2026 Shield volume guidance raised to 230,000-245,000 tests.","Q1 adjusted EBITDA loss of $58.9M relatively flat; free cash flow burn $71.2M; cash position $1.2B."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":301665000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93790,"accession_number":"0001193125-26-182391","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guardant Health CMO Craig Eagle resigns effective May 8, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Craig Eagle resigns as Chief Medical Officer, effective May 8, 2026.","No reason provided for resignation.","No replacement named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105710,"accession_number":"0001576280-26-000012","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q4 revenue $281.3M (+39% YoY); 2026 revenue guided $1.25-1.28B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $281.3M (+39% YoY); Oncology tests 79k (+38%), Screening tests 38k.","Full year 2025 revenue $982.0M (+33%); net loss $416.3M ($3.32 EPS) vs $436.4M prior year.","Adj. EBITDA loss improved to $220.9M (FY) from $257.5M; free cash flow burn $233M vs $275M.","2026 guidance: revenue $1.25-1.28B (27-30% growth); Screening revenue $162-174M; volume 210k-225k tests.","Acquired MetaSight Diagnostics for $59M upfront plus up to $90M contingent consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":982021000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105709,"accession_number":"0001576280-26-000004","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Guardant Health reports Q4 revenue $280M (+39% YoY); full year revenue $981M (+33%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 oncology tests ~79,000 (+38% YoY); full year ~276,000 (+34%).","Shield screening tests surged to ~38,000 in Q4 (vs 6,400 prior year).","Preliminary free cash flow: -$54M Q4, -$233M full year.","Cash and marketable securities ~$1.3B as of Dec 31, 2025.","Results are preliminary and unaudited; final audited results expected Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":982021000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121984,"accession_number":"0001193125-25-272592","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Guardant Health raises ~$717M via upsized equity and convertible debt offerings","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Public offering of 3,833,332 shares at $90/share (incl. underwriter option), net proceeds ~$327.2M.","Convertible notes: $402.5M principal, 0% coupon, due 2033, conversion price ~$121.50/share (35% premium).","Net proceeds from notes ~$390M; combined ~$717M for general corporate purposes, including possible 2027 note repurchase.","Both offerings upsized from initially announced amounts ($250M equity, $300M notes); closed Nov 7, 2025.","Notes convertible under certain conditions after Feb 15, 2033; redeemable after Nov 20, 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121983,"accession_number":"0001576280-25-000276","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q3 revenue $265.2M (+39% YoY); raises FY2025 revenue guidance to $965-$970M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $265.2M (+39% YoY); GAAP net loss $92.7M ($0.74/share), non-GAAP net loss $48.3M ($0.39/share).","Oncology revenue $184.4M (+31%), 74K tests (+40%); Shield screening revenue $24.1M (from $1M), 24K tests.","FY2025 revenue guidance raised to $965-$970M (from $915-$925M), ~31% YoY growth; Screening rev guidance $71-$73M.","Non-GAAP gross margin 66% (up from 63%); cash, equivalents and restricted cash $689.5M.","Shield expanded to multi-cancer detection; Guardant360 Liquid PMA submitted to FDA; new collaborations with Quest and PathGroup."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":700755000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138694,"accession_number":"0001576280-25-000269","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Guardant Health to host Investor Day on September 24, 2025","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Investor Day scheduled for Sept 24, 2025 at 9:00 a.m. ET in New York City.","Presentation by co-CEOs Helmy Eltoukhy and AmirAli Talasaz and executive team.","Company will highlight operations, strategic priorities, and financial outlook.","Live and archived webcast available on Guardant Health's investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138693,"accession_number":"0001576280-25-000267","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Former HHS Secretary Alex Azar appointed to Guardant Health board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alex M. Azar II appointed to Guardant Health board effective Sept 12, 2025; board size increased to 11.","Azar will receive standard non-employee compensation: stock option and RSU each valued at $362,500.","Azar previously served as 24th HHS Secretary (2018-2021) and President of Lilly USA.","Appointed to the nominating and corporate governance committee of the board.","Chairman Helmy Eltoukhy cited Azar's deep operating experience in government and private sector."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138692,"accession_number":"0001576280-25-000245","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q2 revenue $232.1M (+31% YoY); raises FY2025 guidance to $915-925M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $232.1M (+31% YoY); Oncology $158.7M (+22%), Screening $14.8M, Biopharma $56.0M (+28%).","Non-GAAP gross margin 66% (vs 60% YoY); net loss $99.9M ($0.80) vs $102.6M ($0.84) YoY.","2025 revenue guidance raised to $915-925M (24-25% growth) from prior $880-890M; non-GAAP gross margin guidance 63-64%.","Shield screening test volume expected 68,000-73,000; Screening revenue guidance raised to $55-60M.","Free cash flow burn -$65.9M in Q2 vs -$99.1M; core business ex-Screening on track for FCF breakeven in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":435559000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156141,"accession_number":"0001193125-25-143681","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Guardant Health shareholders elect all four director nominees at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Vijaya Gadde, Roberto Mignone, Myrtle Potter, and Musa Tariq elected with 96M, 97M, 97M, and 70M votes for respectively.","Deloitte & Touche LLP ratified as independent auditor for FY2025 with 105.6M votes for, 24.5K against.","Advisory say-on-pay proposal approved with 91.2M for, 7.0M against, and 364K abstentions.","Broker non-votes of 7.2M shares on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156140,"accession_number":"0001576280-25-000135","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q1 revenue $203.5M (+21% YoY); raises FY2025 revenue guidance to $880-$890M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $203.5M, +21% YoY; oncology $150.6M (+20%, 59K tests); screening $5.7M (9K Shield tests); biopharma $45.4M (+21%).","Net loss $95.2M ($0.77/sh) vs $115.0M loss year ago; non-GAAP net loss $61.1M ($0.49/sh); cash $803.9M.","FY2025 revenue guidance raised to $880-$890M (+19-20% YoY) from $850-$860M; screening revenue guided $40-$45M (from $25-$30M).","Non-GAAP gross margin guided 62-63%; FCF burn expected $225-$235M; ex-screening business on track for FCF breakeven in Q4 2025.","Shield received CMS ADLT status ($1,495/test) and VA network coverage covering 9M lives; launched upgraded Guardant360 Tissue test."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":203471000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156139,"accession_number":"0001193125-25-076885","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Guardant Health extends Redwood City lease through 2030/2031; total ~$50M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Third Amendment to lease with Metropolitan Life Insurance Co.; extends term to Dec 31, 2030 or 2031 per building.","Base rent increases 3% annually from 2026; total lease value approximately $50 million.","Annual lease expense will not be materially changed by the amendment.","Original lease dated November 2014; previously amended in October 2017 and March 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174584,"accession_number":"0001576280-25-000043","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q4 revenue up 30% to $201.8M; 2025 revenue guidance $850-860M, convertible debt exchanged","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 revenue $739M (+31% YoY); net loss $436.4M ($3.56 loss per share); non-GAAP net loss $247.2M ($2.01 loss per share).","Q4 2024 revenue $201.8M (+30% YoY); net loss $111M ($0.90 loss per share); non-GAAP net loss $77.3M ($0.62 loss per share).","Completed convertible debt exchange: issued $600M 1.25% 2031 notes, retiring $659.3M of 0% 2027 notes; also repurchased $45M of common stock.","2025 guidance: revenue $850-860M (15-16% growth); oncology clinical volume growth expected to accelerate to ~25%; screening revenue $25-30M on 45-50K Shield tests.","Free cash flow burn improved to $275M in 2024; expects $225-235M in 2025; Guardant Reveal received Medicare coverage for CRC surveillance."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":739016000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174583,"accession_number":"0001193125-25-027362","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Guardant Health issues $600M 1.25% convertible notes due 2031; retires $659.3M of 0% notes due 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $600M new 1.25% convertible notes due 2031 for $659.3M of existing 0% notes due 2027.","After close, $490.7M of 2027 notes remain outstanding; new notes mature Feb 15, 2031.","Initial conversion price ~$62.22/share (35% premium to Feb 6 closing price).","Up to 13,017,960 shares may be issued upon conversion based on initial max conversion rate.","New notes are senior unsecured; interest payable semi-annually at 1.25%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174582,"accession_number":"0001193125-25-022242","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Guardant Health exchanges $659.3M of 0% 2027 notes for $600M of 1.25% 2031 notes; plans $45M buyback","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issues $600M of 1.25% Convertible Senior Notes due Feb 15, 2031, exchanging for $659.3M of 0% Convertible 2027 Notes.","Initial conversion price of new notes ~$62.22/share, a 35% premium to Feb 6, 2025 closing price.","After close (~Feb 14, 2025), $490.7M of 2027 Notes remain outstanding with unchanged terms.","Intends to repurchase ~$45M of common stock from participants; exchange agent will buy ~$35M separately.","New notes are unregistered, issued under Section 4(a)(2) and 3(a)(9) exemptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174581,"accession_number":"0001193125-25-005319","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Guardant Health reports preliminary Q4 revenue ~$200M (+29% YoY); FY24 revenue $737M (+31%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue Q4 ~$200M (+29% YoY); full year ~$737M (+31% YoY).","Oncology clinical tests (ex-Shield) Q4 57,300 (+24%); full year 206,700 (+20%).","Biopharma tests Q4 11,050 (+16%); full year 40,500 (+35%).","Shield screening tests Q4 6,400 with ~$4M revenue in first full commercial quarter.","Free cash flow -$84M in Q4, -$275M full year; cash & securities $944M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":739016000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191543,"accession_number":"0001576280-24-000260","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q3 revenue $191.5M (+34% YoY); raises FY 2024 revenue guidance to $720-725M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $191.5M (+34% YoY); GAAP net loss $107.8M ($0.88/shr), Non-GAAP net loss $55.0M ($0.45/shr).","Clinical test volume 53,100 (+21%), biopharma 10,500 (+40%); Guardant360 ASP >$3,000.","Full-year 2024 revenue guidance raised to $720-725M (prior $690-700M), growth 28-29%.","Free cash flow guidance improved to $(265)-$(275)M, improvement of $70-80M vs 2023.","Shield IVD launched; received Medicare pricing of $920; CMS removed cost-sharing for follow-on colonoscopy."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":537202000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191542,"accession_number":"0001193125-24-242960","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Guardant appoints Roberto Mignone (Bridger Management) to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Guardant expands board to 10; appoints Roberto Mignone as Class I director effective Oct 21, 2024.","Founder and Managing Partner of Bridger Management, a healthcare-focused investment firm.","Appointed to audit committee; receives initial equity awards totaling $725,000 vesting over 4 years.","Appointment follows FDA approval of Shield blood test for early-stage colorectal cancer screening.","Also serves on Teva Pharmaceuticals board and as co-Vice Chairman of NYU Langone Medical Center."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208020,"accession_number":"0001193125-24-206179","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Guardant Health enters ATM sales agreement with Jefferies for up to $400M equity offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement with Jefferies LLC for at-the-market offering of common stock.","Aggregate gross proceeds of up to $400 million; agent compensation up to 3% of gross sales price.","Shares sold under existing shelf registration (Form S-3 filed May 2023); prospectus supplement filed Aug 23, 2024.","Company has no obligation to sell any shares; may suspend or terminate the program at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208019,"accession_number":"0001576280-24-000189","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q2 revenue up 29% to $177.2M, raises FY2024 guidance; FDA approves Shield CRC test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $177.2M (+29% YoY); precision oncology revenue $166.5M (+33%).","GAAP net loss $102.6M ($0.84/share); non-GAAP net loss $58.5M ($0.48 loss).","FY2024 revenue guidance raised to $690-700M (prior $675-685M), growth 22-24%.","Shield blood test received FDA approval for first-line CRC screening; commercial launch; Medicare covers 45M beneficiaries.","Clinical tests 49,400 (+14%), biopharma tests 10,475 (+56%); cash $1.0B."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":345726000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208018,"accession_number":"0001193125-24-186674","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Guardant Health's Shield blood test gets FDA approval for colorectal cancer screening in ages 45+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Shield is first blood test approved by FDA as a primary screening option for colorectal cancer.","Meets CMS requirements for Medicare coverage; expected to be covered for eligible Medicare beneficiaries.","ECLIPSE study showed 83% sensitivity for CRC detection and 90% specificity for advanced neoplasia.","Real-world adherence rate for Shield is over 90%, compared to 28-71% for other screening methods.","Company to launch test soon; commercial insurance coverage expected after future guideline inclusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208017,"accession_number":"0001193125-24-181093","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Guardant Health appoints Dr. Manuel Hidalgo Medina to board effective July 17","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to nine seats; Dr. Hidalgo appointed as Class II director, term expiring at 2026 annual meeting.","Dr. Hidalgo is Chief of Hematology/Medical Oncology at Weill Cornell Medicine and also serves on Bristol-Myers Squibb's board.","Received standard non-employee director compensation: stock option and RSU awards each valued at $362,500, vesting over four years.","Appointed to the nominating and corporate governance committee of the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225555,"accession_number":"0001193125-24-161223","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Guardant Health shareholders reject advisory say-on-pay; director Krognes gets 28% withhold votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advisory vote on named executive officer compensation failed: 84.6M for, 5.8M against, 0.6M abstain.","Director nominee Steve Krognes received 64.4M for and 25.6M withheld (approx 28% withhold).","Other directors Eltoukhy and Talasaz elected with >98% votes for; auditor ratification approved.","Say-on-pay is non-binding but signals shareholder discontent; Krognes opposition notable.","Meeting held June 12, 2024; broker non-votes on director and say-on-pay were 6.2M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225554,"accession_number":"0001193125-24-151836","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Guardant Health amends executive severance plan with enhanced benefits for Co-CEOs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment approved May 24, 2024; applies to all executives including named officers.","Non-CIC termination: 12 months base salary (lump sum), prorated target bonus, 12 months COBRA.","CIC termination: 18 months salary (24 for Co-CEOs), full target bonus, full equity vesting.","Co-CEOs' 2024 long-term awards vest fully on termination before 2026; PSUs vest at up to 250% target if CIC before 2025.","Co-CEOs receive annual RSU/PSU awards in lieu of salary and bonus; severance reflected in accelerated vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225553,"accession_number":"0001193125-24-146510","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA advisory panel strongly recommends approval of Guardant's Shield blood test for CRC screening","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA advisory panel voted 8-1 that Shield is safe, 6-3 that it is effective, and 7-2 that benefits outweigh risks.","Shield blood test showed 83% sensitivity for colorectal cancer detection and 90% specificity for advanced neoplasia in ECLIPSE study.","FDA decision on premarket approval expected later in 2024; Shield is on track to become first FDA-approved blood test for CRC screening.","Approximately 50 million eligible Americans are not up-to-date with CRC screening; Shield offers a blood-draw alternative to stool-based tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225552,"accession_number":"0001576280-24-000108","cik":1576280,"company_name":"Guardant Health, Inc.","ticker":"GH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Guardant Health Q1 revenue up 31% to $168.5M; raises 2024 revenue guidance to $675-685M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $168.5M (+31% YoY); net loss narrowed to $115M ($0.94 loss per share) from $133.5M.","Precision oncology revenue $156.2M (+38%); clinical tests +20%, biopharma tests +37%.","2024 revenue guidance raised to $675-685M (prior $655-670M); FCF guidance improved to $(275)-$(285)M.","Non-GAAP gross margin ex-screening guided to 61%-63% (prior 60%-62%).","ECLIPSE published in NEJM; FDA Advisory Committee on May 23; Shield IVD launch expected post-approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":168491000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":17248597174.11215,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}